Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection

Completed · Phase 2 · Has a placebo group

Conditions studied: Acute Respiratory Infection

In brief

The purpose of this research study is to explore the mechanism of action of Mucinex, an oral, over-the-counter, FDA approved expectorant in patients with acute respiratory tract infections.

Key facts

Study ID

NCT01114581

Run by

Reckitt Benckiser LLC

People needed

38

Starts

2010-04-01

Expected to finish

2011-04-01

Last updated by the study team

2018-09-19

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Symptoms of cough, thickened mucus and chest congestion
• Able to produce sputum
• Non Smoker

You may not qualify if…

• Pregnant
• Smokers
• Fever above 101°F
• Any chronic illness

Where it is running

• Center for Environmental Medicine, Asthma, and Lung Biology — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.